Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy

Journal of Neuro-Oncology

Volumn 58, Issue 2, 2002, Pages 157-165

  Heesters, M A A M ^a   Koudstaal, J ^a   Gwan Go, K ^a   Molenaar, W M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Glioma; MIB 1; p53; Radiotherapy

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ANTIBODY LABELING; APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LONG TERM CARE; MALIGNANT TRANSFORMATION; MEDICAL DOCUMENTATION; MITOSIS; NEUROSURGERY; NICK END LABELING; OLIGODENDROGLIOMA; PATIENT SELECTION; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SCREENING; TREATMENT PLANNING;

APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 0036062988     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016046125698     Document Type: Article

References (46)

1. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: An interim analysis
2. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas
3. Patterns of tumor progression after radiotherapy for low grade gliomas: Analysis from the computed tomography/magnetic resonance imaging era
4. Histologische veranderungen an rontgenbestrahlten gliomen
5. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value
6. Tumor-Suppressor p53: Implications for tumor development and prognosis
7. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins
8. Mitochondria and apoptosis
9. Caspases: Enemies within
10. Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma relapses in vivo
11. P53, the cellular gatekeeper for growth and division
12. p53 status and the efficacy of cancer therapy in vivo
13. Efficiently estimated histologic cell counts
14. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy
15. The p53 gene and protein in human brain tumors
16. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors
17. p53 protein in low grade astrocytomas: A study with a long term follow up
18. Cells with TP 53 mutations in low grade astrocytic tumors evolve clonically to malignancy and are an unfavourable prognostic factor
19. p53 immunoreactivity in astrocytomas and its relationship to survival
20. Assessing TP53 status in human tumours to evaluate clinical outcome
21. Practical value of Ki-67 and p53 labelling indices instereotactic biopsies of diffuse and pilocytic astrocytomas
22. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation
23. MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
24. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations
25. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors
26. Repair of DNA double strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines
27. P53 mutations increase resistance to ionizing radiation
28. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(bax)expression
29. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
30. Expression of bcl2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy
31. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status
32. Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors
33. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas
34. Expression of p53 in oligodendrogliomas
35. P53 immunoreactivity in oligodendrogliomas
36. The prognostic significance of DNA topoisomerase II-alpha (KI-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas
37. Antiapoptotic bcl-2 family protein expression increases with progression of oligodendroglioma
38. Mixed gliomas
39. Supratentorial recurrences of gliomas: Morphological studies in relation to time intervals with astrocytomas
40. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and III gliomas
41. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis
42. Clonal expansion of p53 mutant cells is associate with brain tumour progression
43. Evaluation of malignant features in oligodendroglial tumors
44. Detection of DNA strand breaks associated with apoptosis in human brain tumors
45. BCL-2 family protein expression in initial and recurrent glioblastomas: Modulation by radiochemotherapy